Abstract:Novel bifunctional thienopyridine derivatives linked by an ester bond demonstrate simultaneous targeting of FXa and P2Y12 receptors. These compounds act as mutual prodrugs, combining anticoagulant and antiplatelet activity in a single molecule. This approach offers potential advantages in the treatment of cardiovascular disease through simplified administration and synergistic therapeutic effects. Thienopyridine derivatives are specifically designed for utilization in antithrombotic therapy to help combat cardiovascular disorders linked to thrombosis. This study introduces new thienopyridine derivatives with superior therapeutic efficacy through synergies by dual functional compounds, developed as antithrombotic agents. Through computational design, we discovered 32 compounds out of a library of 100 compounds that exhibit efficacy. The compounds are synthesized by multiple steps and subsequently purified using chromatographic procedures to achieve a purity level of >99%. Using the ADP‐induced platelet aggregation assay, we have found 4 active test compounds (ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03) out of a total of 32 compounds. On the other hand, ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03 have demonstrated the highest percentage activity on factor Xa (FXa) inhibition. The ACG‐A‐04 chemical exhibited the highest hydrophilicity, specifically in terms of its aqueous solubility. It had a solubility of 0.44 mg/mL in pH 5.8, 0.29 mg/L in pH 6.2, and 0.145 mg/L in pH 7.4 buffers. In comparison, the standards APX‐01 (apixaban) and PRG‐01(prasugrel) had lower hydrophilicity. Based on cytotoxicity investigations, it was determined that the test substances do not exhibit harmful effects. The results indicated that the test chemicals can undergo hydrolysis in blood plasma rather than in other organs. Among the four test drugs, ACG‐1073‐19 exhibited an unbound fraction of 44.1%, which is twice as high as the standards (apixaban). ACG‐1073‐37 demonstrates superior plasma protein binding (33.2%) compared to all other test compounds. The compounds resulted in a higher expression of CD61, CD42b, and CD62P in platelets compared to the control. The ACG‐1073‐37 molecule had a Caco‐2 permeability of 51%, which is extremely close to the Caco‐2 permeability of the control medicines (55% for APX‐01 and 62% for PRG‐01). Through the assessment of microsomal stability, it was determined that ACG‐1073‐37 and ACG‐A‐04 exhibited metabolic stability for 42.4 and 34.14 min, respectively.

Study on Antiplatelet Effect of a New Thiophenopyridine Platelets P2Y12 Receptor Antagonist DV-127.

A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y 12 Receptor

Progress in research of P2Y12 receptor antagonists antiplatelet drugs

Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor

Synthesis and Biological Evaluation of Ticagrelor Derivatives As Novel Antiplatelet Agents.

Novel Agents for Anti-Platelet Therapy

Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.

Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice

Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y 1 and P2Y 12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor

Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance.

Optimization of P2Y12 Antagonist Ethyl 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties

Cleavable Novel Thienopyridine Derivatives as Potent Antithrombotic Agents

The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers

BF061, a Novel Antiplatelet and Antithrombotic Agent Targeting P2Y12 Receptor and Phosphodiesterase

A Novel Parenteral Formulation For the Antiplatelet Agent Clopidogrel

Pharmacokinetic/Pharmacodynamic Assessment of the Structural Refinement of Clopidogrel Focusing on the Balance Between Bioactivation and Deactivation

Engineered P2Y12-Overexpressing Cell-Membrane-Wrapped Nanoparticles for the Functional Reversal of Ticagrelor and Clopidogrel

Overcoming Clopidogrel Resistance: Discovery of Vicagrel As a Highly Potent and Orally Bioavailable Antiplatelet Agent

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.

Progress in the clinical effects and adverse reactions of ticagrelor

Current status and progress of percutaneous coronary intervention-related platelet P2Y12 receptor blockers